View ValuationCipher Pharmaceuticals 향후 성장Future 기준 점검 0/6Cipher Pharmaceuticals (는) 각각 연간 2.1% 및 8.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 0.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14% 로 예상됩니다.핵심 정보2.1%이익 성장률0.76%EPS 성장률Pharmaceuticals 이익 성장14.5%매출 성장률8.2%향후 자기자본이익률13.98%애널리스트 커버리지Low마지막 업데이트12 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 30Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026공시 • Apr 21Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026. Location: ontario, toronto Canada공시 • Mar 05Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026공시 • Jan 29Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™? (Spinosad)Cipher Pharmaceuticals Inc. announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™? (Spinosad), for the treatment of head lice and scabies. Natroba™? (Spinosad) is widely recognized as one of the most effective treatments for the two parasitic indications of head lice and sc babies in the U.S. It is superior to the widely used permethrin 1% for treating head lice and is the only treatment in the U.S. that meets the FDA's criteria for a " complete cure" (elimination of all signs and symptoms) in eradicating sc babies infestations with a single application. Cipher acquired Natroba™? (spinosad) in July 2024, and since acquisition has marketed and distributed the product in the United States ("U.S.) market, through its commercial infrastructure.공시 • Oct 30Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025공시 • Aug 28Cipher Pharmaceuticals Inc. Announces the Passing of Board Director and Chairman of Audit Committee Harold M. WolkinCipher Pharmaceuticals Inc. announced the passing of Harold M. Wolkin, a valued member of the Company's Board of Directors and Chairman of the Audit Committee. Mr. Wolkin was a very active member of the Board and his deep understanding of the capital markets and unwavering commitment to the Company's growth and governance were tremendously valuable to the Company. During his tenure, he played a vital role in guiding strategic initiatives, supporting management, and representing the Company and its shareholders with integrity. Harold was a very well-known and highly respective member of the Canadian capital markets community and he will truly be missed by those that knew him.공시 • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025공시 • May 03Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025공시 • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025. Location: ontario, toronto Canada공시 • Mar 12Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025공시 • Nov 04Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024Cipher Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024공시 • Oct 08Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business OfficerCipher Pharmaceuticals Inc. announced the appointment of Hamed Ghanei as Chief Business Officer. Dr. Ghanei has over 15 years of experience in specialty pharmaceuticals, venture funds, and healthcare investment banking. Throughout his career, he has led the evaluation of over 500 licensing and M&A opportunities and has been involved in five commercial product launches. He has successfully negotiated over 20 transactions with total value exceeding $1 billion. Dr. Ghanei holds a B.Sc. from the University of Waterloo, a M.Sc. in Microbiology and Biochemistry from the University of Guelph, and a Ph.D. in Medical Biophysics from the University of Toronto.공시 • Aug 09+ 1 more updateCipher Pharmaceuticals Inc. Announces CFO ChangesEffective August 10, 2024, and as a result of the Natroba Acquisition, Cipher Pharmaceuticals Inc.'s Chief Financial Officer, Bryan Jacobs, will assume the title of President of the Company. His mandate will be to manage the transition and integration of the U.S. operations and commercial sales team. The Company's Vice President, Finance, Ryan Mailling, has in turn been appointed as the Chief Financial Officer of the Company, taking over from Mr. Jacobs.공시 • Aug 02Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024Cipher Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024공시 • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024.공시 • Mar 09Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024Cipher Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Mar 14, 2024공시 • Oct 28Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023Cipher Pharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 09, 2023공시 • Sep 06Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.Cipher Pharmaceuticals Inc. (TSX:CPH) announces a share repurchase program. Under the substantial issuer bid, the company will repurchase up to CAD 6 million worth of its outstanding shares. The shares will be tendered at a price of not less than CAD 3.95 per share and not more than CAD 4.75 per share. The company plans to fund the offer from available cash on hand. The shares purchased under the offer will be cancelled. If the aggregate cost to purchase the tendered shares exceeds $6 million, the company will accept such shares on a pro-rata basis after giving effect to “odd lot” tenders, which will not be subject to pro-ration. The bid will expire on October 11, 2023, unless extended or withdrawn.공시 • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023Cipher Pharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023공시 • May 05Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023Cipher Pharmaceuticals Inc. announced that they will report Q1, 2023 results on May 11, 2023공시 • Feb 14Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023On February 10, 2022, the Board of Directors of Cipher Pharmaceuticals Inc. declared a quarterly dividend of $0.0.01875 per share to shareholders of record on February 21, 2023, payable on or about February 28, 2023.이익 및 매출 성장 예측OTCPK:CPHR.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20286527N/A40212/31/20276226N/A39312/31/20265322302843/31/202651312930N/A12/31/202550273030N/A9/30/202550173030N/A6/30/20254812-5921N/A3/31/2025409-5921N/A12/31/20243312-6020N/A9/30/20242616-6713N/A6/30/202422231717N/A3/31/202422231414N/A12/31/202321201616N/A9/30/202321321515N/A6/30/202320281313N/A3/31/202320271313N/A12/31/202221271111N/A9/30/202222101515N/A6/30/20222181111N/A3/31/20222291111N/A12/31/20212281414N/A9/30/20212251414N/A6/30/20212361212N/A3/31/20212131111N/A12/31/20202241112N/A9/30/202021777N/A6/30/20202231011N/A3/31/20202341112N/A12/31/2019223N/A8N/A9/30/201923-1N/A8N/A6/30/2019222N/A6N/A3/31/2019233N/A2N/A12/31/2018231N/A8N/A9/30/2018286N/A13N/A6/30/2018349N/A18N/A3/31/20183711N/A19N/A12/31/20174011N/A13N/A9/30/2017347N/A11N/A6/30/2017325N/A9N/A3/31/2017311N/A10N/A12/31/2016304N/A11N/A9/30/2016336N/A8N/A6/30/2016342N/A7N/A3/31/2016341N/A7N/A12/31/2015342N/A8N/A9/30/2015323N/A12N/A6/30/20153013N/A16N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CPHR.F 의 연간 예상 수익 증가율(2.1%)이 saving rate(3.5%) 미만입니다.수익 vs 시장: CPHR.F 의 연간 수익(2.1%)이 US 시장(16.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: CPHR.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: CPHR.F 의 수익(연간 8.2%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: CPHR.F 의 수익(연간 8.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CPHR.F의 자본 수익률은 3년 후 14%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 23:02종가2026/05/26 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cipher Pharmaceuticals Inc.는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David NovakATB Cormark Historical (Cormark Securities)Tania Armstrong-WhitworthCanaccord GenuityPrakash GowdCIBC Capital Markets5명의 분석가 더 보기
공시 • Apr 30Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
공시 • Apr 21Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026. Location: ontario, toronto Canada
공시 • Mar 05Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026
공시 • Jan 29Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™? (Spinosad)Cipher Pharmaceuticals Inc. announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™? (Spinosad), for the treatment of head lice and scabies. Natroba™? (Spinosad) is widely recognized as one of the most effective treatments for the two parasitic indications of head lice and sc babies in the U.S. It is superior to the widely used permethrin 1% for treating head lice and is the only treatment in the U.S. that meets the FDA's criteria for a " complete cure" (elimination of all signs and symptoms) in eradicating sc babies infestations with a single application. Cipher acquired Natroba™? (spinosad) in July 2024, and since acquisition has marketed and distributed the product in the United States ("U.S.) market, through its commercial infrastructure.
공시 • Oct 30Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025
공시 • Aug 28Cipher Pharmaceuticals Inc. Announces the Passing of Board Director and Chairman of Audit Committee Harold M. WolkinCipher Pharmaceuticals Inc. announced the passing of Harold M. Wolkin, a valued member of the Company's Board of Directors and Chairman of the Audit Committee. Mr. Wolkin was a very active member of the Board and his deep understanding of the capital markets and unwavering commitment to the Company's growth and governance were tremendously valuable to the Company. During his tenure, he played a vital role in guiding strategic initiatives, supporting management, and representing the Company and its shareholders with integrity. Harold was a very well-known and highly respective member of the Canadian capital markets community and he will truly be missed by those that knew him.
공시 • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025
공시 • May 03Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025
공시 • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025. Location: ontario, toronto Canada
공시 • Mar 12Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025
공시 • Nov 04Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024Cipher Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024
공시 • Oct 08Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business OfficerCipher Pharmaceuticals Inc. announced the appointment of Hamed Ghanei as Chief Business Officer. Dr. Ghanei has over 15 years of experience in specialty pharmaceuticals, venture funds, and healthcare investment banking. Throughout his career, he has led the evaluation of over 500 licensing and M&A opportunities and has been involved in five commercial product launches. He has successfully negotiated over 20 transactions with total value exceeding $1 billion. Dr. Ghanei holds a B.Sc. from the University of Waterloo, a M.Sc. in Microbiology and Biochemistry from the University of Guelph, and a Ph.D. in Medical Biophysics from the University of Toronto.
공시 • Aug 09+ 1 more updateCipher Pharmaceuticals Inc. Announces CFO ChangesEffective August 10, 2024, and as a result of the Natroba Acquisition, Cipher Pharmaceuticals Inc.'s Chief Financial Officer, Bryan Jacobs, will assume the title of President of the Company. His mandate will be to manage the transition and integration of the U.S. operations and commercial sales team. The Company's Vice President, Finance, Ryan Mailling, has in turn been appointed as the Chief Financial Officer of the Company, taking over from Mr. Jacobs.
공시 • Aug 02Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024Cipher Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024
공시 • Apr 09Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024.
공시 • Mar 09Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024Cipher Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Mar 14, 2024
공시 • Oct 28Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023Cipher Pharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 09, 2023
공시 • Sep 06Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.Cipher Pharmaceuticals Inc. (TSX:CPH) announces a share repurchase program. Under the substantial issuer bid, the company will repurchase up to CAD 6 million worth of its outstanding shares. The shares will be tendered at a price of not less than CAD 3.95 per share and not more than CAD 4.75 per share. The company plans to fund the offer from available cash on hand. The shares purchased under the offer will be cancelled. If the aggregate cost to purchase the tendered shares exceeds $6 million, the company will accept such shares on a pro-rata basis after giving effect to “odd lot” tenders, which will not be subject to pro-ration. The bid will expire on October 11, 2023, unless extended or withdrawn.
공시 • Jul 29Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023Cipher Pharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023
공시 • May 05Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023Cipher Pharmaceuticals Inc. announced that they will report Q1, 2023 results on May 11, 2023
공시 • Feb 14Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023On February 10, 2022, the Board of Directors of Cipher Pharmaceuticals Inc. declared a quarterly dividend of $0.0.01875 per share to shareholders of record on February 21, 2023, payable on or about February 28, 2023.